focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

UK launches trial combining different Covid vaccines

Thu, 04th Feb 2021 11:27

(Sharecast News) - The UK has launched the first trial in the world that explores mixing different Covid-19 vaccines for the first and second jab.
According to CNBC, the aim of the trial is to see if employing two dose vaccine regimes using different shots is as effective as using those from the same manufacturer, which would give vaccination programs more flexibility.

The trial is being led by the University of Oxford and run by the National Immunisation Schedule Evaluation Consortium.

"If we do show that these vaccines can be used interchangeably in the same schedule this will greatly increase the flexibility of vaccine delivery, and could provide clues as to how to increase the breadth of protection against new virus strains," Matthew Snape, chief investigator on the trial and associate professor in Paediatrics and Vaccinology at the University of Oxford said on Thursday.

Snape said the study was "tremendously exciting," before adding that "it will provide information vital to the rollout of vaccines in the UK and globally."

The trial, named "Covid-19 Heterologous Prime Boost study", will recruit over 800 volunteers aged 50 and above in England to evaluate the four different combinations of different vaccines.

There are concerns that mixing vaccines could make them less effective but Deputy Chief Medical Officer and Senior Responsible Officer for the study, Professor Jonathan Van-Tam, said that the research could even show that alternating vaccines could enhance the level of antibodies needed to fight the virus.

"It is also even possible that by combining vaccines, the immune response could be enhanced giving even higher antibody levels that last longer; unless this is evaluated in a clinical trial we just won't know. This study will give us greater insight into how we can use vaccines to stay on top of this nasty disease."

Related Shares

More News
Today 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly ...

8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...

8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4% *

8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.